 Following an unblinded, pre-planned interim analysis by the Independent Data Monitoring Committee IDMC, Tonix Pharmaceuticals Holding Corp NASDAQ: TNXP will stop enrollment in the Phase 3 RALLY study of TNX-102 SL cyclobenzaprine HCl sublingual tablets 5.6 mg for fibromyalgia. The IDMC recommended stopping the trial for futility as TNX-102 SL is unlikely to demonstrate a statistically significant improvement in overall change from baseline in pain primary endpoint compared to placebo. 